Research programme: adeno-associated virus gene therapy - Kings College London/Pfizer

Drug Profile

Research programme: adeno-associated virus gene therapy - Kings College London/Pfizer

Alternative Names: AAV gene therapy - Kings College London/Pfizer

Latest Information Update: 06 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Kings College London
  • Developer Alcyone Lifesciences; Kings College London; Pfizer
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Inborn genetic disorders
  • Research Neurodegenerative disorders

Most Recent Events

  • 30 Jun 2017 Pfizer and Alcyone Lifesciences enter into an agreement for the development of adeno-associated virus gene therapy for Neurodegenerative disorders
  • 30 Jun 2017 Early research in Neurodegenerative disorders in USA (Intrathecal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top